On January 6, the U.S. Food and Drug Administration (FDA) granted the first waiver to allow a nucleic acid-based test, the Alere i Influenza A & B test, to be used in a greater variety of healthcare settings. The test uses a nasal swab sample from a patient and provides results in as little as 15 minutes. Negative results don’t rule out influenza virus infection. Read more.
FDA grants waiver for flu test
The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.